These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

483 related items for PubMed ID: 28226419

  • 1. Evaluation of Risk Factors for Clostridium difficile Infection in Hematopoietic Stem Cell Transplant Recipients.
    Scardina TL, Kang Martinez E, Balasubramanian N, Fox-Geiman M, Smith SE, Parada JP.
    Pharmacotherapy; 2017 Apr; 37(4):420-428. PubMed ID: 28226419
    [Abstract] [Full Text] [Related]

  • 2. Oral Vancomycin Prophylaxis as Secondary Prevention Against Clostridioides difficile Infection in the Hematopoietic Stem Cell Transplantation and Hematologic Malignancy Population.
    Morrisette T, Van Matre AG, Miller MA, Mueller SW, Bajrovic V, Abidi MZ, Benamu E, Kaiser JN, Barber GR, Chase S, Tobin J, Fish DN, Gutman JA.
    Biol Blood Marrow Transplant; 2019 Oct; 25(10):2091-2097. PubMed ID: 31255741
    [Abstract] [Full Text] [Related]

  • 3. Clostridium difficile infection after allogeneic hematopoietic stem cell transplantation: incidence, risk factors, and outcome.
    Willems L, Porcher R, Lafaurie M, Casin I, Robin M, Xhaard A, Andreoli AL, Rodriguez-Otero P, Dhedin N, Socié G, Ribaud P, Peffault de Latour R.
    Biol Blood Marrow Transplant; 2012 Aug; 18(8):1295-301. PubMed ID: 22387347
    [Abstract] [Full Text] [Related]

  • 4. Risk factors for the development of Clostridium difficile infection in adult allogeneic hematopoietic stem cell transplant recipients: A single-center study in Québec, Canada.
    Lavallée C, Labbé AC, Talbot JD, Alonso CD, Marr KA, Cohen S, Laverdière M, Dufresne SF.
    Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27943498
    [Abstract] [Full Text] [Related]

  • 5. Risk factors and epidemiology of Clostridium difficile infection in hematopoietic stem cell transplant recipients during the peritransplant period.
    Aldrete SD, Kraft CS, Magee MJ, Chan A, Hutcherson D, Langston AA, Greenwell BI, Burd EM, Friedman-Moraco R.
    Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27943501
    [Abstract] [Full Text] [Related]

  • 6. Clostridium difficile infection in the hematopoietic unit: a meta-analysis of published studies.
    Zacharioudakis IM, Ziakas PD, Mylonakis E.
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1650-4. PubMed ID: 24914822
    [Abstract] [Full Text] [Related]

  • 7. Clostridium difficile infection after allogeneic hematopoietic stem cell transplant: strain diversity and outcomes associated with NAP1/027.
    Kamboj M, Xiao K, Kaltsas A, Huang YT, Sun J, Chung D, Wu S, Sheahan A, Sepkowitz K, Jakubowski AA, Papanicolaou G.
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1626-33. PubMed ID: 24973628
    [Abstract] [Full Text] [Related]

  • 8. Significance of a positive Clostridium difficile toxin test after hematopoietic stem cell transplantation.
    Akahoshi Y, Kimura S, Nakano H, Harada N, Kameda K, Ugai T, Wada H, Yamasaki R, Ishihara Y, Kawamura K, Sakamoto K, Ashizawa M, Sato M, Terasako-Saito K, Nakasone H, Kikuchi M, Yamazaki R, Kanda J, Kako S, Nishida J, Kanda Y.
    Clin Transplant; 2016 Jun; 30(6):703-8. PubMed ID: 27019071
    [Abstract] [Full Text] [Related]

  • 9. Burden of Clostridium difficile infection between 2010 and 2013: Trends and outcomes from an academic center in Eastern Europe.
    Kurti Z, Lovasz BD, Mandel MD, Csima Z, Golovics PA, Csako BD, Mohas A, Gönczi L, Gecse KB, Kiss LS, Szathmari M, Lakatos PL.
    World J Gastroenterol; 2015 Jun 07; 21(21):6728-35. PubMed ID: 26074711
    [Abstract] [Full Text] [Related]

  • 10. Incidence, course, and outcome of Clostridium difficile infection in children with hematological malignancies or undergoing hematopoietic stem cell transplantation.
    Salamonowicz M, Ociepa T, Frączkiewicz J, Szmydki-Baran A, Matysiak M, Czyżewski K, Wysocki M, Gałązka P, Zalas-Więcek P, Irga-Jaworska N, Drożyńska E, Zając-Spychała O, Wachowiak J, Gryniewicz-Kwiatkowska O, Czajńska-Deptuła A, Dembowska-Bagińska B, Chełmecka-Wiktorczyk L, Balwierz W, Bartnik M, Zielezińska K, Urasiński T, Tomaszewska R, Szczepański T, Płonowski M, Krawczuk-Rybak M, Pierlejewski F, Młynarski W, Gamrot-Pyka Z, Woszczyk M, Małas Z, Badowska W, Urbanek-Dądela A, Karolczyk G, Stolpa W, Sobol-Milejska G, Zaucha-Prażmo A, Kowalczyk J, Goździk J, Gorczyńska E, Jermakow K, Król A, Chybicka A, Ussowicz M, Kałwak K, Styczyński J.
    Eur J Clin Microbiol Infect Dis; 2018 Sep 07; 37(9):1805-1812. PubMed ID: 29978303
    [Abstract] [Full Text] [Related]

  • 11. Clostridium difficile colonization and disease in patients undergoing hematopoietic stem cell transplantation.
    Bruminhent J, Wang ZX, Hu C, Wagner J, Sunday R, Bobik B, Hegarty S, Keith S, Alpdogan S, Carabasi M, Filicko-O'Hara J, Flomenberg N, Kasner M, Outschoorn UM, Weiss M, Flomenberg P.
    Biol Blood Marrow Transplant; 2014 Sep 07; 20(9):1329-34. PubMed ID: 24792871
    [Abstract] [Full Text] [Related]

  • 12. Clostridioides difficile infection in solid organ and hematopoietic stem cell transplant recipients: A prospective multinational study.
    Blumberg EA, Collins G, Young JH, Nguyen MH, Michonneau D, Temesgen Z, Origȕen J, Barcan L, Obeid KM, Belloso WH, Gras J, Corbelli GM, Neaton JD, Lundgren J, Snydman DR, Molina JM, INSIGHT Clostridioides difficile Study Group.
    Transpl Infect Dis; 2022 Feb 07; 24(1):e13770. PubMed ID: 34821423
    [Abstract] [Full Text] [Related]

  • 13. Incidence of Clostridium difficile infections in patients receiving antimicrobial and acid-suppression therapy.
    King RN, Lager SL.
    Pharmacotherapy; 2011 Jul 07; 31(7):642-8. PubMed ID: 21923450
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The evaluation of Clostridium difficile infection (CDI) in a community hospital.
    Daniel A, Rapose A.
    J Infect Public Health; 2015 Jul 07; 8(2):155-60. PubMed ID: 25301221
    [Abstract] [Full Text] [Related]

  • 17. Retrospective evaluation of fidaxomicin versus oral vancomycin for treatment of Clostridium difficile infections in allogeneic stem cell transplant.
    Prohaska L, Mahmoudjafari Z, Shune L, Singh A, Lin T, Abhyankar S, Ganguly S, Grauer D, McGuirk J, Clough L.
    Hematol Oncol Stem Cell Ther; 2018 Dec 07; 11(4):233-240. PubMed ID: 29928848
    [Abstract] [Full Text] [Related]

  • 18. A retrospective review of metronidazole and vancomycin in the management of Clostridium difficile infection in patients with hematologic malignancies.
    Parmar SR, Bhatt V, Yang J, Zhang Q, Schuster M.
    J Oncol Pharm Pract; 2014 Jun 07; 20(3):172-82. PubMed ID: 23804627
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Risk factors for recurrent Clostridium difficile infection in a tertiary hospital in Israel.
    Na'amnih W, Adler A, Miller-Roll T, Cohen D, Carmeli Y.
    Eur J Clin Microbiol Infect Dis; 2018 Jul 07; 37(7):1281-1288. PubMed ID: 29627951
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.